---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-102447"
form_type: "8-K"
ticker: "CRBP"
cik: "0001595097"
company_name: "Corbus Pharmaceuticals Holdings, Inc."
filed_at: "2025-08-05T23:59:59+00:00"
generated_at: "2026-05-17T20:44:06.039814+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Corbus Pharmaceuticals Q2 2025 Net Loss $17.7M, Pipeline on Track for Data Readouts H2 2025

## Summary
- Net loss for Q2 2025 was $17.7 million ($1.44 per share), compared to $10.0 million loss in Q2 2024.
- Cash and investments totaled $116.6 million as of June 30, 2025, expected to fund operations through Q2 2027.
- Phase 1/2 dose expansion data for Nectin-4 ADC CRB-701 to be presented at ESMO 2025 in October.
- Obesity drug CRB-913 initiated multiple ascending dose portion; SAD/MAD data expected later in 2025.
- FDA granted Fast Track designation for CRB-701 in relapsed/refractory metastatic cervical cancer.

## SEC filing metadata
- accession: 0000950170-25-102447
- form_type: 8-K
- ticker: CRBP
- cik: 0001595097
- company_name: Corbus Pharmaceuticals Holdings, Inc.
- filed_at: 2025-08-05T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1595097/000095017025102447/0000950170-25-102447-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1595097/000095017025102447/crbp-20250805.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-102447
- JSON: https://secwatch.observer/filing/0000950170-25-102447.json
- Plain text: https://secwatch.observer/filing/0000950170-25-102447.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.